Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 15/20 | 0.49 |
| ▸ | RPTOR | Q8N122 | 10/20 | 0.49 |
| ▸ | MLST8 | Q9BVC4 | 10/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.31 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155973 | 0.92 | MTOR (0.60) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL135874 | 0.92 | MTOR (0.60) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522112 | 0.92 | MTOR (0.53) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL154222 | 0.92 | MTOR (0.60) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522278 | 0.92 | MTOR (0.60) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522245 | 0.92 | MTOR (0.60) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL138609 | 0.92 | MTOR (0.53) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL138213 | 0.85 | MTOR (0.43) | MTORRPTORMLST8PIK3CA | |
| SCHEMBL156434 | 0.78 | MTOR (0.54) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL156427 | 0.78 | MTOR (0.54) | MTORRPTORMLST8PIK3CACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059164-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | PERRIN-NINKOVIC SOPHIE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059164-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.